(Bloomberg) -The stock price of ELI LILLY & CO. helps the patient to help the patient gain weight and control the blood sugar. Stocks from the sender of this drug, Chugai Pharmaceutical Co., Ltd. have also surged.
I read the most in Bloomberg
Related drugs, including Ozempic, a blockbuster diabetes taken by Novo Nordisk A/S, and related drugs, including Zepbound and Mounjaro, have made all their efforts to develop drugs for easy to take. Rivals, including pfizer Inc., were frustrated, but analysts said that success is important for creating a $ 130 billion market forecast by the end of 10 years.
The results of the Lilly Funds Support Research provide a promising first shape. Diabetes patients have lost 16 pounds of 16 pounds or weight for 40 weeks. It was more than a similar patient than a similar patient in the initial study of Ozempic. At the end of this study, people who are receiving pills did not hit weight high and suggested that they could lose more. Blood sugar levels decreased by 1.3%, slightly low in competitors.
JEFERIES analyst Akash Tewari said, “Data presents the best scenario for the release of blockbusters in the gate.Jared Holz, a medical expert in Mizuho, said,“ Lilly said, It will remain a famous player for a while in the category. ”
LILLY surged 14%in New York trading on Thursday, which has gained the most profitable profit for more than a year. Chugai recorded 16%in Tokyo trading on Friday and has gained the largest commercial profit for more than four years.
But the trial is not decisive. Lilly is one of some other relevant states, such as diabetes, obesity and sleep apnea. According to the clinical trial database, the main obesity test is not packed at least July, and the result is one of the most expected results of this year. According to Dave Ricks, Lily can launch medicine in early 2026.
Blockbuster boom
The obesity shots created by Novo and Lilly have gained popularity and generated billions of dollars in sales. However, drugs that can be collected by mouth rather than injections are considered the following border. But science can be difficult.
